Can Tailored Patient Letters Improve The Quality Of Diabetic Patient Care?
|ClinicalTrials.gov Identifier: NCT00984841|
Recruitment Status : Completed
First Posted : September 25, 2009
Last Update Posted : September 25, 2009
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus||Other: Tailored letter||Not Applicable|
Diabetes care in the US is less than optimal. Some authors have found that targeted patient letters are also an effective tool to improve outcomes when they are part of a comprehensive disease management plan. Local patient satisfaction surveys had revealed that many patients had sub‐optimal understanding of diabetes measures and of the importance of controlling these measures to reduce diabetic complications. We wondered if tailored patient letters and enclosed lab orders when due might increase patient awareness of diabetes measures and increase patient engagement.We hypothesized that the addition of targeted patient letters with enclosed lab orders to an ongoing performance improvement program would further improve diabetes care.
We conducted a randomized controlled study of tailored patient letters and diabetes lab orders at our two resident‐based clinics.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||467 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Can Tailored Patient Letters Improve The Quality Of Diabetic Patient Care?"|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||April 2009|
|Actual Study Completion Date :||July 2009|
Experimental: Tailored letter
Patients in the tailored letter group received by mail a tailored letter detailing their diabetes measures, together with enclosed orders for lab tests when due, and reminder of or scheduling for an office appointment.
Other: Tailored letter
Active Comparator: Usual Care
Patients in the usual care group were part of a practice wide quality improvement process.
Other: Tailored letter
- Diabetes summary quality measure [ Time Frame: 4 months ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00984841
|United States, Pennsylvania|
|Scranton-Temple Health Center|
|Scranton, Pennsylvania, United States, 18510|
|Principal Investigator:||John R Guzek, MD||Scranton-Temple Residency Program|